

RUBRA MEDICAMENTS LIMITED

Statement of Standalone Unaudited Financial Results for the quarter and Half year ended September 30, 2017

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceding 3 months ended	Figures for corresponding 3 months ended in the previous year	Year to date Figures for current period ended	Year to date Figures for previous period ended	Figures for the previous year ended
		30-Sep-2017	30-Jun-2017	30-Sep-2016	30-Sep-2017	30-Sep-2016	31-Mar-2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	103.42	92.30	7.88	195.72	15.13	30.62
II	Other Income	9.28	6.70	0.00	15.98	0.00	0.25
III	Total Income (I + II)	112.70	99.00	7.88	211.70	15.13	30.87
IV	Expenses:						
	Cost of Materials Consumed	0	0.00	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	101.53	86.94	4.36	188.47	7.93	12.13
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	3.08	0.32	0.45	3.40	0.90	2.00
	Finance Costs	0.00	0.00	0.00	0.00	0.00	0.01
	Depreciation & amortisation expense	0.01	0.01	0.01	0.02	0.01	0.03
	Other Expenses	5.05	6.66	2.03	11.71	4.79	13.31
	Total Expenses (IV)	109.67	93.93	6.85	203.60	13.63	27.48
V	Profit / (loss) before exceptional items and tax (III-IV)	3.03	5.07	1.03	8.10	1.50	3.39
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit / (loss) before tax (V-VI)	3.03	5.07	1.03	8.10	1.50	3.39
VIII	Tax Expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	3.03	5.07	1.03	8.10	1.50	3.39
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinuing operations (after tax)(X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX+XII)	3.03	5.07	1.03	8.10	1.50	3.39
XIV	Other comprehensive income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	3.03	5.07	1.03	8.10	1.50	3.39
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic	0.06	0.09	0.02	0.15	0.03	0.06
	(2) Diluted	0.06	0.09	0.02	0.15	0.03	0.06
XVII	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	Earnings per equity share (for discontinued & continuing operation):						
	(1) Basic	0.06	0.09	0.02	0.15	0.03	0.06
	(2) Diluted	0.06	0.09	0.02	0.15	0.03	0.06
1	NOTES:						
2	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.						
3	The Segment - wise details are not applicable to the Company as the Company has no segments.						
4	The results are Ind-AS compliant however, the previous year figures are not subject to limit review or audit. However the management has exercised necessary due - diligence to ensure that the Financial Results provide a true and fair view of its affairs.						
5	The result is provisional and unaudited and subject to change, regrouping and restatement.						

For Rubra Medicaments Limited

Place: Mumbai
Date:- November 10, 2017


Abha Kapoor
 Director (Finance) & CFO
 DIN: 02799429

RUBRA MEDICAMENTS LIMITED

(Rs. in Lakhs)

STATEMENT OF ASSETS AND LIABILITIES

	Particulars	Figures as at the end of current reporting period	Figures as at the end of the previous reporting period
		September 30, 2017	March 31, 2017
		Unaudited	Audited
	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	0.06	0.08
	(b) Capital work-in-progress	-	-
	(c) Investment property	-	-
	(d) Goodwill	-	-
	(e) Other intangible assets	-	-
	(f) Intangible assets under development	-	-
	(g) Biological assets other than bearer plants	-	-
	(h) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	-	-
	(iii) Loans	-	-
	(iv) Others (to be specified) - Advances	38.89	33.79
	(i) Deferred tax assets (net)	-	-
	(j) Other non-current assets	1.69	1.69
	Total non-current assets	40.64	35.56
2	Current assets		
	(a) Inventories	2.37	-
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	1.77	1.77
	(iii) Cash and cash equivalents	25.09	15.55
	(iv) Bank balances other than (iii) above	-	-
	(v) Loans	-	-
	(vi) Others to be specified - Advances	-	-
	(c) Current tax assets (net)	-	-
	(d) Other current assets	-	-
	Total current assets	29.23	17.32
	Total assets	69.87	52.88
1	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital	546.83	546.83
	(b) Other equity	-496.93	-505.03
	Total equity	49.90	41.80
	LIABILITIES		
2	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	-	-
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (net)	7.47	7.47
	(d) Other non-current liabilities	-	-
	Total non-current liabilities	7.47	7.47
	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	10.00	-
	(ii) Trade payables	2.32	3.32
	(iii) Other financial liabilities (other than those specified in item (a))	-	-
	(b) Other current liabilities	-	-
	(c) Provisions, current	0.18	0.29
	(d) Current tax liabilities (Net)	-	-
	Total current liabilities	12.50	3.61
	Total liabilities	19.97	11.08
	Total Equity and Liabilities	69.87	52.88